Spectral Medical (EDT) Q3 2024 earnings summary

Executive summary

• Focused on developing and commercializing PMX for septic shock, with ongoing legacy reagent sales.

• Revenue for nine months ended September 30, 2024 was $1,641,000, up from $1,233,000 year-over-year.

• Net loss for nine months ended September 30, 2024 was $18,556,000, compared to $9,184,000 in the prior year period.

• Significant uncertainty exists regarding going concern due to dependence on FDA approval, commercialization, and additional funding.

Financial highlights

• Cash at September 30, 2024 was $5,759,000, up from $2,952,000 at December 31, 2023.

• Total assets increased to $11,996,000 from $8,219,000 at year-end 2023.

• Total liabilities rose to $39,501,000 from $21,760,000 at December 31, 2023, driven by higher notes payable and derivative liabilities.

• Shareholders' deficiency widened to $(31,282,000) from $(16,549,000) at year-end.

• Net cash used in operating activities for nine months was $6,523,000, compared to $8,576,000 in the prior year.

Outlook and guidance

• Continued focus on obtaining FDA approval and commercializing PMX.

• Additional capital required for clinical, regulatory, and commercialization activities; sources may include equity, debt, or partnerships.

• No assurance of sufficient capital; failure to raise funds may require curtailment of operations.